Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature

BACKGROUND: Immune checkpoint inhibitors are novel therapies with indications for treating several solid cancers. They are associated with immune-related adverse events, which are generally well tolerated. Though rare, severe side effects may be life-threatening. One such adverse event is Guillain-B...

Descripción completa

Detalles Bibliográficos
Autores principales: Gravbrot, Nicholas, Scherer, Katalin, Sundararajan, Srinath
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893263/
https://www.ncbi.nlm.nih.gov/pubmed/31885974
http://dx.doi.org/10.1155/2019/5490707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893263/
https://www.ncbi.nlm.nih.gov/pubmed/31885974
http://dx.doi.org/10.1155/2019/5490707

Ejemplares similares